Precision Oncology

Pioneer in Early Discovery of Malignant Tumors

Each year, more than 15 million people are diagnosed with cancer. Cancer is a group of heterogeneous diseases that can affect almost any part of the body and has many anatomic and molecular subtypes, each requiring specific diagnostic and management strategies. It is estimated that more than half of all cancer deaths could be prevented, and it is well established that early detection of cancer improves cancer mortality. Thus, an enhanced focus on early detection and prevention should be a priority to

reduce the burden of cancer. Early diagnosis is most effective for cancers that can be identified at an early stage and treated effectively. Understanding the effectiveness and cost of interventions for common cancer types is critical when prioritizing strategies

Innovative Discovery & Technology

BioLabs International is ready to license the patents that was innovated Case Western Reserve University in the United States. It’s planned to turn the innovative technology into a series of medical diagnostics pipeline so as to commercialize for meeting the needs in today’s cancer diagnostic environment.

Today, cancers are most commonly detected by ultrasound, MRI, CT-scan or biopsy. Doctors and researchers agree that current cancer detection techniques are ineffective. Cancer is caused by an accumulation of genetic mutations and therefore needs to be caught early before the disease progresses. Many researchers believe that cancer biomarkers, small abnormalities in the body’s chemical or genetic composition can be detected in the very early stages of cancer, aiding in early diagnosis. these mutations or abnormalities can act as nucleic acid-based biomarkers in diagnosis. By looking for small abnormalities, cancer can be detected before the tumor has time to grow. Also, most of the biomarkers have demonstrated sufficient sensitivity and specificity for translation into routine clinical use or for treatment monitoring.


A biosensor is a receptor-transducer device that is designed to detect a biological analyte, be it environmental or biological in origin (i.e, within the human body). Information such as whether the analyte is present and at what level is transduced into an electrical signal that can be amplified, displayed, and analyzed. This innovative technology platforms provides a reliable and cost-effective in vitro assay technique to detect samples of human whole blood, plasma, serum or urine, with sample size on the order of microliters. The test platforms can be simplified as rapid, portable and point of care diagnostic products. and it's currently estimated a low-cost solution. Our technology has made a breakthrough to develop electroanalytical devices that are able to capture biologically significant biomarkers for breast cancers or for prostate cancers and their byproducts to quantitatively measure indications of clinically important diseases.